[go: up one dir, main page]

BRPI0406689A - Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório - Google Patents

Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório

Info

Publication number
BRPI0406689A
BRPI0406689A BR0406689-8A BRPI0406689A BRPI0406689A BR PI0406689 A BRPI0406689 A BR PI0406689A BR PI0406689 A BRPI0406689 A BR PI0406689A BR PI0406689 A BRPI0406689 A BR PI0406689A
Authority
BR
Brazil
Prior art keywords
antibody
vitro method
inflammatory disorder
diagnosing
course
Prior art date
Application number
BR0406689-8A
Other languages
English (en)
Inventor
Marie-Francoise Belin
Pascale Giraudon
Laurence Boumsell
Armand Bensussan
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of BRPI0406689A publication Critical patent/BRPI0406689A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"USO DE UM ANTICORPO BD16 E/OU BB18 ANTI-CD100 E MéTODO IN VITRO PARA DIAGNóSTICO OU DETERMINAçãO DA EVOLUçãO DE UM DISTúRBIO INFLAMATóRIO". A invenção refere-se ao uso de um anticorpo BD16 e/ou BB18 antí-CD100 ou de uma forma quimérica ou humanizada ou humana do mesmo, ou um fragmento do mesmo, para a terapia ou o diagnóstico de um distúrbio do sistema nervoso central, mais particularmente um distúrbio de mielina ou uma doença que afeta os oligodendrócitos, tais como a esclerose múltipla ou a mielopatia associada a HTLV-1 ou células de mielinação periféricas.
BR0406689-8A 2003-01-31 2004-02-02 Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório BRPI0406689A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290247A EP1442749A1 (en) 2003-01-31 2003-01-31 Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
PCT/EP2004/001743 WO2004067034A1 (en) 2003-01-31 2004-02-02 Use of anti-cd100 antibodies

Publications (1)

Publication Number Publication Date
BRPI0406689A true BRPI0406689A (pt) 2005-12-20

Family

ID=32605433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406689-8A BRPI0406689A (pt) 2003-01-31 2004-02-02 Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório

Country Status (11)

Country Link
US (2) US8067247B2 (pt)
EP (2) EP1442749A1 (pt)
JP (1) JP4768597B2 (pt)
BR (1) BRPI0406689A (pt)
CA (1) CA2514226C (pt)
CY (1) CY1112953T1 (pt)
DK (1) DK1587542T3 (pt)
ES (1) ES2388735T3 (pt)
PT (1) PT1587542E (pt)
SI (1) SI1587542T1 (pt)
WO (1) WO2004067034A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576754B2 (en) * 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
DE602008004296D1 (de) * 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
AU2010245668B2 (en) * 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
EP2487242A1 (en) * 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
US9447191B2 (en) 2011-05-13 2016-09-20 National University Corporation Tokyo Medical And Dental University Osteogenesis promoter
US20130095118A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) * 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
JP6611709B2 (ja) 2013-06-25 2019-11-27 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP3241844B1 (en) 2014-12-03 2021-04-21 Aimed Bio Inc. Antibody against neuropilin 1 and use thereof
NZ786461A (en) 2016-04-22 2025-10-31 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
US11085930B2 (en) 2016-06-03 2021-08-10 Aimed Bio Inc. Anti-NRP1 antibody screening method
CA3032512C (en) 2016-08-02 2025-05-06 Vaccinex, Inc. IMPROVED PROCESSES FOR PRODUCING POLYNUCLEOTIDE LIBRARIES IN VACCINE VIRUS/EUKARYOTIC CELLS
AU2018237549B2 (en) 2017-03-20 2024-08-01 Vaccinex, Inc. Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
US11427634B2 (en) 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
CN112566664B (zh) * 2018-07-19 2023-08-25 国立大学法人东京大学 Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
IL284981B2 (en) 2019-03-28 2025-11-01 Vaccinex Inc Semaphorin-4d antagonists for use in cancer therapy
WO2021021991A1 (en) 2019-08-01 2021-02-04 Vaccinex,Inc. Combined inhibition of semaphorin-4d and tgfb and compositions therefor
EP4172205A1 (en) 2020-06-25 2023-05-03 Vaccinex, Inc. Use of semaphorin-4d binding molecules for the treatment of rett syndrome
KR20240063995A (ko) 2021-09-27 2024-05-10 백시넥스 인코포레이티드 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
CN117866091A (zh) * 2022-10-12 2024-04-12 三优生物医药(上海)有限公司 抗cd100抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686087A1 (fr) * 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US6576754B2 (en) * 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6635742B1 (en) * 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system

Also Published As

Publication number Publication date
JP4768597B2 (ja) 2011-09-07
PT1587542E (pt) 2012-07-18
EP1442749A1 (en) 2004-08-04
ES2388735T3 (es) 2012-10-18
DK1587542T3 (da) 2012-07-30
JP2006516594A (ja) 2006-07-06
US20060233793A1 (en) 2006-10-19
EP1587542A1 (en) 2005-10-26
EP1587542B1 (en) 2012-06-13
CY1112953T1 (el) 2016-04-13
WO2004067034A1 (en) 2004-08-12
US20120027758A1 (en) 2012-02-02
SI1587542T1 (sl) 2012-10-30
CA2514226C (en) 2015-04-28
CA2514226A1 (en) 2004-08-12
US8067247B2 (en) 2011-11-29

Similar Documents

Publication Publication Date Title
BRPI0406689A (pt) Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório
Ogrodnik et al. Whole‐body senescent cell clearance alleviates age‐related brain inflammation and cognitive impairment in mice
Hidaka et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin
Mielenz et al. EFhd2/Swiprosin-1 is a common genetic determinator for sensation-seeking/low anxiety and alcohol addiction
Zhang et al. Degradation of NLRP3 by p62‐dependent‐autophagy improves cognitive function in Alzheimer's disease by maintaining the phagocytic function of microglia
Maina et al. Serum levels of brain-derived neurotrophic factor in drug-naive obsessive–compulsive patients: a case–control study
Colaianna et al. Soluble βamyloid1‐42: a critical player in producing behavioural and biochemical changes evoking depressive‐related state?
Errico et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice
Zurawek et al. Reciprocal MicroRNA expression in mesocortical circuit and its interplay with serotonin transporter define resilient rats in the chronic mild stress
Paco et al. Cyclic AMP signaling restricts activation and promotes maturation and antioxidant defenses in astrocytes
BR112013008573A2 (pt) citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
US20150233939A1 (en) Methods and compositions for biomarkers of fatigue
Biswas et al. Comparative study of neurological soft signs in schizophrenia with onset in childhood, adolescence and adulthood
BRPI0515560A (pt) memantina para o tratamento de distúrbios comportamentais infantis
Lipina et al. Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice
Freemantle et al. Cholesterol and phospholipids in frontal cortex and synaptosomes of suicide completers: relationship with endosomal lipid trafficking genes
Amoruso et al. Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients
AR124974A1 (es) Proteínas y metabolitos biomarcadores en sangre para el diagnóstico del síndrome de brugada
Hermine et al. Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease
BR0211697A (pt) Marcador de câncer e usos deste na diagnose de câncer
WO2010033951A3 (en) Methods for identification and prediction of multiple sclerosis disease and therapy response
Zeng et al. A high‐salt diet disturbs the development and function of natural killer cells in mice
Patergnani et al. Pathogenetic involvement of autophagy and mitophagy in primary progressive multiple sclerosis
Liu et al. cDNA microarray analysis of gene expression in the cerebral cortex and hippocampus of BALB/c mice subjected to chronic mild stress

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 36 (TRINTA E SEIS) DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]